ubiquitin conjugating enzyme E2 S pseudogene 1Genealiases: []
Q-omics provides the consensus-scored UBE2SP1 profile across patient tissues and cancer cell-line models. UBE2SP1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UBE2SP1 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, UBE2SP1 RNA expression shows 16,805 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where UBE2SP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2SP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2SP1 survival associations across molecular data types. UBE2SP1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2SP1 RNA expression–survival associations across cancer types. High UBE2SP1 expression shows unfavorable associations in ACC, KIRC, KICH, KIRP, LIHC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UBE2SP1 RNA expression.
This table summarizes UBE2SP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2SP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2SP1 shows higher tumor expression in COAD, HNSC, LIHC, LUSC, STAD and LUAD. The COAD box plot shows higher UBE2SP1 RNA expression in tumor versus normal tissue (log2 FC = +1.740, t-test p < 0.001).
This table shows molecular features associated with UBE2SP1 in patient tissues and cancer cell lines. In patient samples, UBE2SP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
